[Federal Register Volume 79, Number 173 (Monday, September 8, 2014)]
[Notices]
[Pages 53174-53175]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-21308]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

[Docket No.: PTO-P-2014-0028]


Grant of Interim Extension of the Term of U.S. Patent No. 
5,686,060; LUMASONTM (sulfur hexafluoride microbubble)

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of Interim Patent Term Extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued an 
order granting interim extension under 35 U.S.C. 156(d)(5) for a one-
year interim extension of the term of U.S. Patent No. 5,686,060.

FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 
272-7755; by mail marked to her attention and addressed to the 
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, 
Alexandria, VA 22313-

[[Page 53175]]

1450; by fax marked to her attention at (571) 273-7755; or by email to 
[email protected].

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, 
generally provides that the term of a patent may be extended for a 
period of up to five years if the patent claims a product, or a method 
of making or using a product, that has been subject to certain defined 
regulatory review, and that the patent may be extended for interim 
periods of up to one year if the regulatory review is anticipated to 
extend beyond the expiration date of the patent.
    On May 13, 2014, Bracco Suisse SA, the patent owner of record, 
timely filed an application under 35 U.S.C. Sec.  156(d)(5) for an 
interim extension of the term of U.S. Patent No. 5,686,060. The patent 
claims the human drug product LUMASONTM, sulfur hexafluoride 
microbubbles. The application indicates that Bracco Diagnostics Inc., 
an affiliate of patent owner Bracco Suisse SA, initially submitted a 
New Drug Application (NDA) #21-315 to the Food and Drug 
Administration (FDA) on January 21, 2001, and withdrew NDA #21-
315 on December 20, 2007. Bracco Diagnostics Inc. submitted a new NDA 
#203-684 on December 20, 2011. FDA accepted NDA 203-684 for 
filing on February 19, 2012.
    Review of the application indicates that, except for permission to 
market or use the product commercially, the subject patent would be 
eligible for an extension of the patent term under 35 U.S.C. 156, and 
that the patent should be extended for one year as required by 35 
U.S.C. 156(d)(5)(B). Because the regulatory review period will continue 
beyond the original expiration date of the patent, November 11, 2014, 
interim extension of the patent term under 35 U.S.C. 156(d)(5) is 
appropriate.
    An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. 
Patent No. 5,686,060 is granted for a period of one year from the 
original expiration date of the patent.

    Dated: August 26, 2014.
Andrew Hirshfeld.
Deputy Commissioner for Patent Examination Policy, United States Patent 
and Trademark Office.
[FR Doc. 2014-21308 Filed 9-5-14; 8:45 am]
BILLING CODE 3510-16-P